Report

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.3 STUDY SCOPE 40
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 40
1.3.2 INCLUSIONS & EXCLUSIONS 41
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 42
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 43
2 RESEARCH METHODOLOGY 44
2.1 RESEARCH DATA 44
2.1.1 SECONDARY RESEARCH 45
2.1.1.1 Key secondary sources 45
2.1.1.2 Key data from secondary sources 46
2.1.2 PRIMARY RESEARCH 46
2.1.2.1 Key primary sources 47
2.1.2.2 Key objectives of primary research 47
2.1.2.3 Key data from primary sources 48
2.1.2.4 Key industry insights 49
2.2 MARKET SIZE ESTIMATION 51
2.2.1 BOTTOM-UP APPROACH 51
2.2.2 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS 52
2.2.3 TOP-DOWN APPROACH 53
2.3 DATA TRIANGULATION 54
2.4 MARKET SHARE ANALYSIS 55
2.5 STUDY ASSUMPTIONS 55
2.5.1 MARKET ASSUMPTIONS 55
2.5.2 GROWTH RATE ASSUMPTIONS 55
2.6 RESEARCH LIMITATIONS 56
2.6.1 METHODOLOGY-RELATED LIMITATIONS 56
2.6.2 SCOPE-RELATED LIMITATIONS 56
2.7 RISK ANALYSIS 56
3 EXECUTIVE SUMMARY 57
?
4 PREMIUM INSIGHTS 63
4.1 IMMUNOASSAY MARKET OVERVIEW 63
4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY 64
4.3 IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT 65
4.4 IMMUNOASSAY MARKET: REGIONAL MIX 66
5 MARKET OVERVIEW 67
5.1 INTRODUCTION 67
5.2 MARKET DYNAMICS 67
5.2.1 DRIVERS 68
5.2.1.1 Increasing incidence of chronic and infectious diseases 68
5.2.1.1.1 Increased use of immunoassays in oncology 69
5.2.1.1.2 Rising use of immunoassays in diagnostic applications 70
5.2.1.1.3 High geriatric population 71
5.2.1.2 Increased demand for blood donations in healthcare systems and surgical procedures 72
5.2.1.3 Growth in biotechnology & biopharmaceutical industries 72
5.2.1.4 Increasing adoption of immunoassay-based POC and rapid testing 73
5.2.1.5 Supportive government regulatory policies and initiatives 74
5.2.1.6 Increased consumption of drugs, alcohol, and cannabis 74
5.2.2 RESTRAINTS 75
5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables 75
5.2.2.2 Technical hurdles of immunoassay kits 75
5.2.3 OPPORTUNITIES 76
5.2.3.1 Increasing growth opportunities in emerging economies 76
5.2.3.2 Focus on importance of companion diagnostics 77
5.2.3.3 Development of condition-specific biomarkers and tests 78
5.2.3.4 Integration of microfluidics in immunoassays 79
5.2.3.5 Improving immunoassay diagnostic technologies 79
5.2.4 CHALLENGES 80
5.2.4.1 Design challenges and low quality of antibodies 80
5.2.4.2 Dearth of skilled professionals 80
5.3 REGULATORY ANALYSIS 80
5.3.1 REGULATORY FRAMEWORK 80
5.3.1.1 North America 80
5.3.1.1.1 US 80
5.3.1.1.2 Canada 82
5.3.1.2 Europe 82
5.3.1.2.1 Russia 83
?
5.3.1.3 Asia Pacific 83
5.3.1.3.1 Japan 83
5.3.1.3.2 China 85
5.3.1.3.3 India 85
5.3.1.3.4 Indonesia 86
5.3.1.3.5 South Korea 87
5.3.1.4 Middle East 87
5.3.1.4.1 Saudi Arabia 87
5.3.1.5 Latin America 88
5.3.1.5.1 Mexico 88
5.3.1.5.2 Brazil 89
5.3.1.6 Africa 90
5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
5.4 TECHNOLOGY ANALYSIS 92
5.4.1 KEY TECHNOLOGIES 92
5.4.1.1 ELISA 92
5.4.2 ADJACENT TECHNOLOGIES 92
5.4.2.1 Microfluidics and miniaturized platforms 92
5.4.3 COMPLEMENTARY TECHNOLOGIES 92
5.4.3.1 Lateral flow assays 92
5.5 TRADE ANALYSIS 94
5.5.1 IMPORT DATA FOR HS CODE 382200, 2019-2024 94
5.5.2 EXPORT DATA FOR HS CODE 382200, 2019-2024 95
5.6 PATENT ANALYSIS 96
5.7 VALUE CHAIN ANALYSIS 97
5.8 SUPPLY CHAIN ANALYSIS 98
5.9 ECOSYSTEM ANALYSIS 99
5.9.1 ROLE IN ECOSYSTEM 100
5.10 PORTER'S FIVE FORCES ANALYSIS 101
5.10.1 INTENSITY OF COMPETITIVE RIVALRY 102
5.10.2 BARGAINING POWER OF SUPPLIERS 102
5.10.3 BARGAINING POWER OF BUYERS 102
5.10.4 THREAT OF SUBSTITUTES 102
5.10.5 THREAT OF NEW ENTRANTS 102
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 103
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 103
5.11.2 KEY BUYING CRITERIA 103
5.12 KEY CONFERENCES & EVENTS, 2025-2026 104
?
5.13 PRICING ANALYSIS 105
5.13.1 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,
BY KEY PLAYER, 2022-2024 105
5.13.2 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY ANAYZERS,
BY REGION, 2022-2024 106
5.13.3 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,
BY TYPE, 2022-2024 107
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 108
5.15 CASE STUDY ANALYSIS 109
5.15.1 PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING 109
5.15.2 MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION 109
5.15.3 LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING 110
5.16 INVESTMENT & FUNDING SCENARIO 110
5.17 IMPACT OF AI/GEN AI ON IMMUNOASSAY MARKET 111
5.17.1 MARKET POTENTIAL FOR IMMUNOASSAY PRODUCTS 111
5.17.2 FUTURE OF AI/GEN AI IN IMMUNOASSAY MARKET 112
5.18 IMPACT OF 2025 US TARIFF ON IMMUNOASSAY MARKET 113
5.18.1 INTRODUCTION 113
5.18.2 KEY TARIFF RATES 113
5.18.3 PRICE IMPACT ANALYSIS 114
5.18.4 IMPACT ON COUNTRY/REGION 115
5.18.4.1 North America 115
5.18.4.1.1 US 115
5.18.4.2 Europe 115
5.18.4.2.1 Germany 115
5.18.4.2.2 UK and France 115
5.18.4.3 Asia Pacific 116
5.18.4.3.1 China 116
5.18.4.3.2 Japan 116
5.18.4.3.3 India 116
5.18.5 IMPACT ON END-USE INDUSTRIES 116
5.18.5.1 Hospitals & clinics 116
5.18.5.2 Clinical laboratories 117
5.18.5.3 Blood banks 117
5.18.5.4 Home care settings 117
?
6 IMMUNOASSAY MARKET, BY PRODUCT 118
6.1 INTRODUCTION 119
6.2 REAGENTS & KITS 119
6.2.1 ELISA REAGENTS & KITS 124
6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment 124
6.2.2 RAPID TEST REAGENTS & KITS 127
6.2.2.1 High demand for preliminary screening tests in remote areas to propel segment growth 127
6.2.3 ELISPOT REAGENTS & KITS 130
6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to aid segment growth 130
6.2.4 CLIA REAGENTS & KITS 133
6.2.4.1 Better diagnosis and higher specificity to augment segment growth 133
6.2.5 IFA REAGENTS & KITS 136
6.2.5.1 Better adaptability in clinical diagnostics to support segment growth 136
6.2.6 WESTERN BLOT REAGENTS & KITS 139
6.2.6.1 Western blot reagents & kits to be considered gold standard for infectious disease test result validation 139
6.2.7 OTHER REAGENTS & KITS 142
6.3 ANALYZERS 144
6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE 148
6.3.1.1 Open-ended systems 149
6.3.1.1.1 Better flexibility and wider availability to drive segment growth 149
6.3.1.2 Closed-ended systems 152
6.3.1.2.1 Higher precision and better automation to fuel segment growth 152
6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE 154
6.3.2.1 Rental purchase 155
6.3.2.1.1 Increased convenience and reduced liability to boost segment growth 155
6.3.2.2 Outright purchase 157
6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market growth 157
7 IMMUNOASSAY MARKET, BY TECHNOLOGY 160
7.1 INTRODUCTION 161
7.2 ELISA 164
7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET 164
7.3 CLIA 168
7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO AID MARKET GROWTH 168
?
7.4 IFA 171
7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND
NON-BIOLOGICAL MOLECULES 171
7.5 RAPID TESTS 174
7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE ADOPTION IN POINT-OF-CARE DIAGNOSIS AND EMERGENCY CARE SETTINGS 174
7.6 WESTERN BLOTTING 177
7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO SPUR MARKET GROWTH 177
7.7 ELISPOT 180
7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO PROPEL MARKET GROWTH 180
7.8 OTHER TECHNOLOGIES 183
8 IMMUNOASSAY MARKET, BY SPECIMEN 187
8.1 INTRODUCTION 188
8.2 BLOOD 191
8.2.1 HIGH RELIABILITY AND INCREASED NEED DURING SURGICAL PROCEDURES TO AID MARKET GROWTH 191
8.3 SALIVA 194
8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO AUGMENT MARKET GROWTH 194
8.4 URINE 197
8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO FAVOR MARKET GROWTH 197
8.5 OTHER SPECIMENS 200
9 IMMUNOASSAY MARKET, BY APPLICATION 204
9.1 INTRODUCTION 205
9.2 INFECTIOUS DISEASES 208
9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET 208
9.3 ENDOCRINOLOGY 212
9.3.1 RISING INCIDENCE OF DIABETES TO AUGMENT MARKET GROWTH 212
9.4 CARDIOLOGY 215
9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH 215
9.5 AUTOIMMUNE DISORDERS 219
9.5.1 HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO AUGMENT MARKET GROWTH 219
9.6 ALLERGY DIAGNOSTICS 222
9.6.1 GROWING PREVALENCE OF ALLERGIES TO AID MARKET GROWTH 222
9.7 ONCOLOGY 225
9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO PROPEL MARKET GROWTH 225
?
9.8 BONE & MINERAL DISORDERS 228
9.8.1 INCREASING PREVALENCE OF OSTEOPOROSIS, VITAMIN D DEFICIENCY, AND ARTHRITIS TO AID MARKET GROWTH 228
9.9 DRUG MONITORING & TESTING 232
9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO ACCELERATE MARKET GROWTH 232
9.10 BLOOD SCREENING 236
9.10.1 RISING EMPHASIS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH 236
9.11 NEWBORN SCREENING 239
9.11.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH 239
9.12 OTHER APPLICATIONS 243
10 IMMUNOASSAY MARKET, BY END USER 246
10.1 INTRODUCTION 247
10.2 HOSPITALS & CLINICS 250
10.2.1 GROWING PATIENT POPULATION AND RISING TESTING VOLUME TO DRIVE MARKET 250
10.3 CLINICAL LABORATORIES 254
10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET 254
10.4 HOME CARE SETTINGS 257
10.4.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO PROPEL MARKET GROWTH 257
10.5 BLOOD BANKS 260
10.5.1 INCREASING NUMBER OF ACCIDENTS AND RISING DEMAND FOR BLOOD DURING SURGERIES TO SPUR MARKET GROWTH 260
11 IMMUNOASSAY MARKET, BY REGION 264
11.1 INTRODUCTION 265
11.2 NORTH AMERICA 265
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 266
11.2.2 US 272
11.2.2.1 US to dominate North American immunoassay market during forecast period 272
11.2.3 CANADA 278
11.2.3.1 Increasing government support and rising incidence of chronic diseases to augment market growth 278
11.3 EUROPE 283
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 283
11.3.2 GERMANY 289
11.3.2.1 High healthcare spending and favorable government initiatives to propel market growth 289
11.3.3 ITALY 294
11.3.3.1 Rising geriatric population and increasing cancer prevalence to spur market growth 294
11.3.4 FRANCE 298
11.3.4.1 Increased use of POC testing and favorable reimbursement policies to boost market growth 298
11.3.5 SPAIN 303
11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to augment market growth 303
11.3.6 UK 307
11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market 307
11.3.7 RUSSIA 313
11.3.7.1 Increasing access to quality healthcare and developing pharmaceutical industry to favor market growth 313
11.3.8 REST OF EUROPE 317
11.4 ASIA PACIFIC 322
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 322
11.4.2 JAPAN 328
11.4.2.1 Increasing investments in healthcare technologies and research activities to fuel market growth 328
11.4.3 CHINA 333
11.4.3.1 Increasing government investments and rising geriatric population to accelerate maket growth 333
11.4.4 INDIA 337
11.4.4.1 Growing medical tourism and improving healthcare infrastructure to propel market growth 337
11.4.5 AUSTRALIA 342
11.4.5.1 Increasing incidence of cancer and rising focus on blood donations to favor market growth 342
11.4.6 SOUTH KOREA 347
11.4.6.1 Rising healthcare spending and increasing research investments to fuel market growth 347
11.4.7 INDONESIA 351
11.4.7.1 High geriatric population and favorable government healthcare policies to accelerate market growth 351
11.4.8 REST OF ASIA PACIFIC 356
11.5 LATIN AMERICA 360
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 360
11.5.2 BRAZIL 365
11.5.2.1 High incidence of infectious diseases and presence of academic & research institutes to boost market growth 365
11.5.3 MEXICO 370
11.5.3.1 Increasing geriatric population and rising popularity of medical tourism to propel market growth 370
11.5.4 REST OF LATIN AMERICA 374
11.6 MIDDLE EAST & AFRICA 379
11.6.1 LACK OF SKILLED LABORATORY PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT MARKET GROWTH 379
12 COMPETITIVE LANDSCAPE 384
12.1 INTRODUCTION 384
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 384
12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET 384
12.3 REVENUE ANALYSIS, 2020-2024 386
12.4 MARKET SHARE ANALYSIS, 2024 386
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 388
12.5.1 STARS 388
12.5.2 EMERGING LEADERS 388
12.5.3 PERVASIVE PLAYERS 389
12.5.4 PARTICIPANTS 389
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 390
12.5.5.1 Company footprint 390
12.5.5.2 Region footprint 391
12.5.5.3 Product footprint 392
12.5.5.4 Specimen footprint 393
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 394
12.6.1 PROGRESSIVE COMPANIES 394
12.6.2 RESPONSIVE COMPANIES 394
12.6.3 DYNAMIC COMPANIES 394
12.6.4 STARTING BLOCKS 394
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 396
12.6.5.1 List of key startups/SMEs 396
12.6.5.2 Competitive benchmarking of key startups/SMEs 397
12.7 COMPANY VALUATION & FINANCIAL METRICS 398
12.7.1 FINANCIAL METRICS 398
12.7.2 COMPANY VALUATION 398
12.8 BRAND/PRODUCT COMPARISON 399
12.9 COMPETITIVE SCENARIO 399
12.9.1 PRODUCT LAUNCHES/APPROVALS/ ENHANCEMENTS 399
12.9.2 DEALS 400
13 COMPANY PROFILES 402
13.1 KEY PLAYERS 402
13.1.1 ABBOTT 402
13.1.1.1 Business overview 402
13.1.1.2 Products offered 403
13.1.1.3 Recent developments 405
13.1.1.3.1 Product approvals 405
13.1.1.3.2 Deals 406
13.1.1.3.3 Expansions 407
13.1.1.4 MnM view 407
13.1.1.4.1 Right to win 407
13.1.1.4.2 Strategic choices 407
13.1.1.4.3 Weaknesses & competitive threats 407
13.1.2 F. HOFFMANN-LA ROCHE LTD. 408
13.1.2.1 Business overview 408
13.1.2.2 Products offered 409
13.1.2.3 Recent developments 412
13.1.2.3.1 Product launches and approvals 412
13.1.2.3.2 Deals 412
13.1.2.3.3 Expansions 413
13.1.2.4 MnM view 413
13.1.2.4.1 Right to win 413
13.1.2.4.2 Strategic choices 414
13.1.2.4.3 Weaknesses & competitive threats 414
13.1.3 SIEMENS HEALTHINEERS AG 415
13.1.3.1 Business overview 415
13.1.3.2 Products offered 416
13.1.3.3 Recent developments 418
13.1.3.3.1 Product launches and approvals 418
13.1.3.3.2 Deals 418
13.1.3.3.3 Expansions 419
13.1.3.4 MnM view 420
13.1.3.4.1 Right to win 420
13.1.3.4.2 Strategic choices 420
13.1.3.4.3 Weaknesses & competitive threats 420
13.1.4 DANAHER 421
13.1.4.1 Business overview 421
13.1.4.2 Products offered 422
13.1.4.3 Recent developments 423
13.1.4.3.1 Product launches and approvals 423
13.1.4.3.2 Deals 424
13.1.4.3.3 Expansions 425
13.1.4.4 MnM view 426
13.1.4.4.1 Right to win 426
13.1.4.4.2 Strategic choices 426
13.1.4.4.3 Weaknesses & competitive threats 426
13.1.5 THERMO FISHER SCIENTIFIC INC. 427
13.1.5.1 Business overview 427
13.1.5.2 Products offered 428
13.1.5.3 Recent developments 429
13.1.5.3.1 Product approvals 429
13.1.5.3.2 Deals 430
13.1.5.4 MnM view 430
13.1.5.4.1 Right to win 430
13.1.5.4.2 Strategic choices 431
13.1.5.4.3 Weaknesses & competitive threats 431
13.1.6 REVVITY 432
13.1.6.1 Business overview 432
13.1.6.2 Products offered 433
13.1.6.3 Recent developments 434
13.1.6.3.1 Product approvals 434
13.1.6.3.2 Other developments 435
13.1.7 BECTON, DICKINSON AND COMPANY (BD) 436
13.1.7.1 Business overview 436
13.1.7.2 Products offered 437
13.1.7.3 Recent developments 438
13.1.7.3.1 Expansions 438
13.1.8 DIASORIN S.P.A. 439
13.1.8.1 Business overview 439
13.1.8.2 Products offered 440
13.1.8.3 Recent developments 442
13.1.8.3.1 Product launches and approvals 442
13.1.8.3.2 Deals 443
13.1.9 BIO-RAD LABORATORIES, INC. 444
13.1.9.1 Business overview 444
13.1.9.2 Products offered 445
13.1.9.3 Recent developments 447
13.1.9.3.1 Product launches 447
13.1.9.3.2 Deals 448
13.1.10 QUIDELORTHO CORPORATION 449
13.1.10.1 Business overview 449
13.1.10.2 Products offered 450
13.1.10.3 Recent developments 453
13.1.10.3.1 Product approvals 453
13.1.10.3.2 Deals 453
13.1.10.3.3 Expansions 454
13.1.11 BIOMERIEUX 455
13.1.11.1 Business overview 455
13.1.11.2 Products offered 456
13.1.11.3 Recent developments 457
13.1.11.3.1 Product launches and approvals 457
13.1.11.3.2 Deals 458
?
13.1.12 QIAGEN 459
13.1.12.1 Business overview 459
13.1.12.2 Products offered 460
13.1.12.3 Recent developments 461
13.1.12.3.1 Deals 461
13.1.13 SYSMEX CORPORATION 462
13.1.13.1 Business overview 462
13.1.13.2 Products offered 464
13.1.13.3 Recent developments 464
13.1.13.3.1 Deals 464
13.1.13.3.2 Expansions 465
13.1.14 AGILENT TECHNOLOGIES, INC. 467
13.1.14.1 Business overview 467
13.1.14.2 Products offered 468
13.1.14.3 Recent developments 469
13.1.14.3.1 Product launches and approvals 469
13.1.14.3.2 Deals 469
13.1.14.3.3 Other developments 470
13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 471
13.1.15.1 Business overview 471
13.1.15.2 Products offered 472
13.2 OTHER PLAYERS 473
13.2.1 MERCK KGAA 473
13.2.2 MERIDIAN BIOSCIENCE 474
13.2.3 BIO-TECHNE 475
13.2.4 CELLABS 476
13.2.5 ABNOVA CORPORATION 477
13.2.6 J. MITRA & CO. PVT. LTD. 477
13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES) 478
13.2.8 CELL SCIENCES 478
13.2.9 ENZO BIOCHEM INC. 479
13.2.10 CREATIVE DIAGNOSTICS 480
13.2.11 BOSTER BIOLOGICAL TECHNOLOGY 480
13.2.12 ELABSCIENCE BIONOVATON INC. 481
13.2.13 WAK-CHEMIE MEDICAL GMBH 481
13.2.14 SERA CARE 482
13.2.15 EPITOPE DIAGNOSTICS, INC. 482
13.2.16 KAMIYA BIOMEDICAL COMPANY 483
13.2.17 GYROS PROTEIN TECHNOLOGIES AB 483
13.2.18 TRIVITRON HEALTHCARE 484
13.2.19 INBIOS INTERNATIONAL, INC. 484
13.2.20 MACCURA BIOTECHNOLOGY CO., LTD. 485
14 APPENDIX 486
14.1 DISCUSSION GUIDE 486
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 490
14.3 CUSTOMIZATION OPTIONS 492
14.4 RELATED REPORTS 492

TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS 41
TABLE 2 IMMUNOASSAY MARKET: KEY DATA FROM PRIMARY SOURCES 48
TABLE 3 IMMUNOASSAY MARKET: MARKET ASSUMPTIONS 55
TABLE 4 IMMUNOASSAY MARKET: RISK ANALYSIS 56
TABLE 5 INCREASING INCIDENCE OF CANCER, BY REGION,
2020 VS. 2030 VS. 2040 (MILLION) 69
TABLE 6 PROJECTED NUMBER OF CANCER PATIENTS, BY CANCER TYPE,
2015 VS. 2018 VS. 2035 (UNITS) 70
TABLE 7 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING 70
TABLE 8 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION,
2022 VS. 2030 VS. 2050 71
TABLE 9 RECENT DEVELOPMENTS IN IMMUNOASSAY MARKET, 2021-2023 77
TABLE 10 NEW TESTS LAUNCHED BY KEY PLAYERS, 2021-2023 78
TABLE 11 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS 79
TABLE 12 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS 81
TABLE 13 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES 82
TABLE 14 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES 83
TABLE 15 JAPAN: CLASSIFICATION OF IN-VIRTO DIAGNOSTIC REAGENTS 84
TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
TABLE 17 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
TABLE 18 INDONESIA: REGISTRATION PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 86
TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 87
TABLE 20 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 88
TABLE 21 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 27 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES 93
TABLE 28 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES
IN IMMUNOASSAY MARKET 94
TABLE 29 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION) 95
TABLE 30 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION) 95
TABLE 31 IMMUNOASSAY MARKET: ROLE IN ECOSYSTEM 100
TABLE 32 IMMUNOASSAY MARKET: PORTER'S FIVE FORCES 101
TABLE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 103
TABLE 34 KEY BUYING CRITERIA, BY END USER 104
TABLE 35 IMMUNOASSAY MARKET: LIST OF KEY CONFERENCES & EVENTS,
JANUARY 2025-DECEMBER 2026 104
TABLE 36 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022-2024 (USD) 105
TABLE 37 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS,
BY REGION, 2022-2024 (USD) 106
TABLE 38 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE,
2022-2024 (USD) 107
TABLE 39 CASE STUDY 1: PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING 109
TABLE 40 CASE STUDY 2: MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY
CANCER DETECTION 109
TABLE 41 CASE STUDY 3: LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING 110
TABLE 42 US ADJUSTED RECIPROCAL TARIFF RATES 113
TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 119
TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET 120
TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION,
2023-2030 (USD MILLION) 121
TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION) 121
TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 122
TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 122
TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 123
TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 123
TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION) 125
TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 125
TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 126
TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 126
TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 127
TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION) 128
TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 128
TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 129
TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 129
TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 130
TABLE 61 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION) 131
TABLE 62 NORTH AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 131
TABLE 63 EUROPE: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 132
TABLE 64 ASIA PACIFIC: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 132
TABLE 65 LATIN AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 133
TABLE 66 CLIA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION) 134
TABLE 67 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 134
TABLE 68 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 135
TABLE 69 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 135
TABLE 70 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 136
TABLE 71 IFA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION) 136
TABLE 72 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 137
TABLE 73 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 137
TABLE 74 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 138
TABLE 75 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 138
TABLE 76 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION,
2023-2030 (USD MILLION) 139
TABLE 77 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 140
TABLE 78 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 140
TABLE 79 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 141
TABLE 80 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 141
TABLE 81 OTHER REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION) 142
TABLE 82 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 142
TABLE 83 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 143
TABLE 84 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 143
TABLE 85 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 144
TABLE 86 KEY ANALYZERS AVAILABLE IN MARKET 145
TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2023-2030 (USD MILLION) 146
TABLE 88 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 146
TABLE 89 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 147
TABLE 90 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 147
TABLE 91 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 148
TABLE 92 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 149
TABLE 93 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2023-2030 (USD MILLION) 149
TABLE 94 NORTH AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 150
TABLE 95 EUROPE: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 150
TABLE 96 ASIA PACIFIC: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 151
TABLE 97 LATIN AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 151
TABLE 98 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2023-2030 (USD MILLION) 152
TABLE 99 NORTH AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 152
TABLE 100 EUROPE: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 153
TABLE 101 ASIA PACIFIC: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 153
TABLE 102 LATIN AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 154
TABLE 103 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 154
TABLE 104 RENTAL PURCHASE MARKET, BY REGION, 2023-2030 (USD MILLION) 155
TABLE 105 NORTH AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 155
TABLE 106 EUROPE: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 156
TABLE 107 ASIA PACIFIC: RENTAL PURCHASE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 156
TABLE 108 LATIN AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 157
TABLE 109 OUTRIGHT PURCHASE MARKET, BY REGION, 2023-2030 (USD MILLION) 157
TABLE 110 NORTH AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 158
TABLE 111 EUROPE: OUTRIGHT PURCHASE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 158
TABLE 112 ASIA PACIFIC: OUTRIGHT PURCHASE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 159
TABLE 113 LATIN AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 159
TABLE 114 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 161
TABLE 115 IMMUNOASSAY TECHNOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION) 161
TABLE 116 NORTH AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 162
TABLE 117 EUROPE: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 162
TABLE 118 ASIA PACIFIC: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 163
TABLE 119 LATIN AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 163
TABLE 120 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET 164
TABLE 121 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2023-2030 (USD MILLION) 165
TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 166
TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 166
TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 167
TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 167
TABLE 126 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2023-2030 (USD MILLION) 169
TABLE 127 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,
2023-2030 (USD MILLION) 169
TABLE 128 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,
2023-2030 (USD MILLION) 170
TABLE 129 ASIA PACIFIC: IMMUNOASSAY MARKET CLIA, BY COUNTRY,
2023-2030 (USD MILLION) 170
TABLE 130 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,
2023-2030 (USD MILLION) 171
TABLE 131 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2023-2030 (USD MILLION) 172
TABLE 132 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,
2023-2030 (USD MILLION) 172
TABLE 133 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,
2023-2030 (USD MILLION) 173
TABLE 134 ASIA PACIFIC: IMMUNOASSAY MARKET IFA, BY COUNTRY,
2023-2030 (USD MILLION) 173
TABLE 135 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,
2023-2030 (USD MILLION) 174
TABLE 136 KEY RAPID TESTS AVAILABLE IN MARKET 174
TABLE 137 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION,
2023-2030 (USD MILLION) 175
TABLE 138 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION) 175
TABLE 139 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,
2023-2030 (USD MILLION) 176
TABLE 140 ASIA PACIFIC: IMMUNOASSAY MARKET RAPID TESTS, BY COUNTRY,
2023-2030 (USD MILLION) 176
TABLE 141 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,
2023-2030 (USD MILLION) 177
TABLE 142 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 177
TABLE 143 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION,
2023-2030 (USD MILLION) 178
TABLE 144 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING,
BY COUNTRY, 2023-2030 (USD MILLION) 178
TABLE 145 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY,
2023-2030 (USD MILLION) 179
TABLE 146 ASIA PACIFIC: IMMUNOASSAY MARKET WESTERN BLOTTING, BY COUNTRY,
2023-2030 (USD MILLION) 179
TABLE 147 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION) 180
TABLE 148 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2023-2030 (USD MILLION) 181
TABLE 149 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY,
2023-2030 (USD MILLION) 181
TABLE 150 EUROPE: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY,
2023-2030 (USD MILLION) 182
TABLE 151 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY,
2023-2030 (USD MILLION) 182
TABLE 152 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY,
2023-2030 (USD MILLION) 183
TABLE 153 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2023-2030 (USD MILLION) 184
TABLE 154 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023-2030 (USD MILLION) 184
TABLE 155 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION) 185
TABLE 156 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION) 185
TABLE 157 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023-2030 (USD MILLION) 186
TABLE 158 IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 188
TABLE 159 IMMUNOASSAY SPECIMEN MARKET, BY REGION, 2023-2030 (USD MILLION) 188
TABLE 160 NORTH AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 189
TABLE 161 EUROPE: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 189
TABLE 162 ASIA PACIFIC: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 190
TABLE 163 LATIN AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 190
TABLE 164 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2023-2030 (USD MILLION) 192
TABLE 165 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY,
2023-2030 (USD MILLION) 192
TABLE 166 EUROPE: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY,
2023-2030 (USD MILLION) 193
TABLE 167 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY,
2023-2030 (USD MILLION) 193
TABLE 168 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY,
2023-2030 (USD MILLION) 194
TABLE 169 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2023-2030 (USD MILLION) 195
TABLE 170 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY,
2023-2030 (USD MILLION) 195
TABLE 171 EUROPE: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY,
2023-2030 (USD MILLION) 196
TABLE 172 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY,
2023-2030 (USD MILLION) 196
TABLE 173 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY,
2023-2030 (USD MILLION) 197
TABLE 174 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2023-2030 (USD MILLION) 198
TABLE 175 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY,
2023-2030 (USD MILLION) 198
TABLE 176 EUROPE: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY,
2023-2030 (USD MILLION) 199
TABLE 177 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY,
2023-2030 (USD MILLION) 199
TABLE 178 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY,
2023-2030 (USD MILLION) 200
TABLE 179 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION,
2023-2030 (USD MILLION) 201
TABLE 180 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION) 201
TABLE 181 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY,
2023-2030 (USD MILLION) 202
TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION) 202
TABLE 183 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION) 203
TABLE 184 IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 205
TABLE 185 IMMUNOASSAY APPLICATION MARKET, BY REGION, 2023-2030 (USD MILLION) 206
TABLE 186 NORTH AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 206
TABLE 187 EUROPE: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 207
TABLE 188 ASIA PACIFIC: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 207
TABLE 189 LATIN AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 208
TABLE 190 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION,
2023-2030 (USD MILLION) 209
TABLE 191 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 210
TABLE 192 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION) 210
TABLE 193 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION) 211
TABLE 194 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 211
TABLE 195 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION,
2023-2030 (USD MILLION) 212
TABLE 196 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION) 213
TABLE 197 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY,
2023-2030 (USD MILLION) 213
TABLE 198 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION) 214
TABLE 199 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION) 214
TABLE 200 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS 216
TABLE 201 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION,
2023-2030 (USD MILLION) 216
TABLE 202 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION) 217
TABLE 203 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,
2023-2030 (USD MILLION) 217
TABLE 204 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,
2023-2030 (USD MILLION) 218
TABLE 205 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,
2023-2030 (USD MILLION) 218
TABLE 206 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION,
2023-2030 (USD MILLION) 219
TABLE 207 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 220
TABLE 208 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 220
TABLE 209 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 221
TABLE 210 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 221
TABLE 211 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,
2023-2030 (USD MILLION) 222
TABLE 212 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 223
TABLE 213 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION) 223
TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION) 224
TABLE 215 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 224
TABLE 216 INCREASING INCIDENCE OF CANCER, BY REGION,
2021 VS. 2030 VS. 2040 (MILLION) 225
TABLE 217 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION) 226
TABLE 218 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,
2023-2030 (USD MILLION) 226
TABLE 219 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,
2023-2030 (USD MILLION) 227
TABLE 220 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,
2023-2030 (USD MILLION) 227
TABLE 221 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,
2023-2030 (USD MILLION) 228
TABLE 222 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS 229
TABLE 223 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION,
2023-2030 (USD MILLION) 230
TABLE 224 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 230
TABLE 225 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 231
TABLE 226 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 231
TABLE 227 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 232
TABLE 228 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 233
TABLE 229 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 233
TABLE 230 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION,
2023-2030 (USD MILLION) 234
TABLE 231 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION) 234
TABLE 232 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2023-2030 (USD MILLION) 235
TABLE 233 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2023-2030 (USD MILLION) 235
TABLE 234 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2023-2030 (USD MILLION) 236
TABLE 235 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION,
2023-2030 (USD MILLION) 237
TABLE 236 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION) 237
TABLE 237 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY,
2023-2030 (USD MILLION) 238
TABLE 238 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION) 238
TABLE 239 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION) 239
TABLE 240 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING 239
TABLE 241 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION,
2023-2030 (USD MILLION) 240
TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,
BY COUNTRY, 2023-2030 (USD MILLION) 241
TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION) 241
TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION) 242
TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,
BY COUNTRY, 2023-2030 (USD MILLION) 242
TABLE 246 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,
2023-2030 (USD MILLION) 243
TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023-2030 (USD MILLION) 244
TABLE 248 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION) 244
TABLE 249 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION) 245
TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023-2030 (USD MILLION) 245
TABLE 251 IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 247
TABLE 252 IMMUNOASSAY END USER MARKET, BY REGION, 2023-2030 (USD MILLION) 247
TABLE 253 NORTH AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 248
TABLE 254 EUROPE: IMMUNOASSAY END USER MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 248
TABLE 255 ASIA PACIFIC: IMMUNOASSAY END USER MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 249
TABLE 256 LATIN AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 249
TABLE 257 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION,
2023-2030 (USD MILLION) 251
TABLE 258 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023-2030 (USD MILLION) 252
TABLE 259 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION) 252
TABLE 260 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION) 253
TABLE 261 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023-2030 (USD MILLION) 253
TABLE 262 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION,
2023-2030 (USD MILLION) 255
TABLE 263 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2023-2030 (USD MILLION) 255
TABLE 264 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION) 256
TABLE 265 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2023-2030 (USD MILLION) 256
TABLE 266 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2023-2030 (USD MILLION) 257
TABLE 267 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION,
2023-2030 (USD MILLION) 258
TABLE 268 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2023-2030 (USD MILLION) 258
TABLE 269 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION) 259
TABLE 270 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION) 259
TABLE 271 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2023-2030 (USD MILLION) 260
TABLE 272 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION,
2023-2030 (USD MILLION) 261
TABLE 273 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION) 261
TABLE 274 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,
2023-2030 (USD MILLION) 262
TABLE 275 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,
2023-2030 (USD MILLION) 262
TABLE 276 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION) 263
TABLE 277 IMMUNOASSAY MARKET, BY REGION, 2023-2030 (USD MILLION) 265
TABLE 278 NORTH AMERICA: KEY MACROINDICATORS 266
TABLE 279 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 268
TABLE 280 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 268
TABLE 281 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 269
TABLE 282 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 269
TABLE 283 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION) 270
TABLE 284 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 270
TABLE 285 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,
2023-2030 (USD MILLION) 271
TABLE 286 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 271
TABLE 287 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER,
2023-2030 (USD MILLION) 272
TABLE 288 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED,
2022-2030 (BILLION UNITS) 273
TABLE 289 US: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 274
TABLE 290 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 274
TABLE 291 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 275
TABLE 292 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 275
TABLE 293 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 276
TABLE 294 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 276
TABLE 295 US: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 277
TABLE 296 US: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 277
TABLE 297 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034 278
TABLE 298 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 279
TABLE 299 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 279
TABLE 300 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 280
TABLE 301 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 280
TABLE 302 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 281
TABLE 303 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 281
TABLE 304 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 282
TABLE 305 CANADA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 282

TABLE 306 EUROPE: KEY MACROINDICATORS 284
TABLE 307 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 284
TABLE 308 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 285
TABLE 309 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 285
TABLE 310 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 286
TABLE 311 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 286
TABLE 312 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 287
TABLE 313 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 287
TABLE 314 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 288
TABLE 315 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 288
TABLE 316 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 290
TABLE 317 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 290
TABLE 318 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 291
TABLE 319 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 291
TABLE 320 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 292
TABLE 321 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 292
TABLE 322 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 293
TABLE 323 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 293
TABLE 324 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 294
TABLE 325 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 295
TABLE 326 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 295
TABLE 327 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 296
TABLE 328 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 296
TABLE 329 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 297
TABLE 330 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 297
TABLE 331 ITALY: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 298
TABLE 332 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 299
TABLE 333 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 299
TABLE 334 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 300
TABLE 335 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 300
TABLE 336 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 301
TABLE 337 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 301
TABLE 338 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 302
TABLE 339 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 302
TABLE 340 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 303
TABLE 341 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 304
TABLE 342 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 304
TABLE 343 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 305
TABLE 344 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 305
TABLE 345 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 306
TABLE 346 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 306
TABLE 347 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 307
TABLE 348 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 309
TABLE 349 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 309
TABLE 350 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 310
TABLE 351 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 310
TABLE 352 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 311
TABLE 353 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 311
TABLE 354 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 312
TABLE 355 UK: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 312
TABLE 356 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 313
TABLE 357 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 314
TABLE 358 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 314
TABLE 359 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 315
TABLE 360 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 315
TABLE 361 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 316
TABLE 362 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 316
TABLE 363 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 317
TABLE 364 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 318
TABLE 365 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 318
TABLE 366 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 319
TABLE 367 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION) 319
TABLE 368 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 320
TABLE 369 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN,
2023-2030 (USD MILLION) 320
TABLE 370 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 321
TABLE 371 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER,
2023-2030 (USD MILLION) 321
TABLE 372 ASIA PACIFIC: KEY MACROINDICATORS 322
TABLE 373 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 324
TABLE 374 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 324
TABLE 375 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 325
TABLE 376 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 325
TABLE 377 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 326
TABLE 378 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 326
TABLE 379 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 327
TABLE 380 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 327
TABLE 381 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 328
TABLE 382 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 329
TABLE 383 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 329
TABLE 384 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 330
TABLE 385 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 330
TABLE 386 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 331
TABLE 387 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 331
TABLE 388 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 332
TABLE 389 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 332
TABLE 390 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 333
TABLE 391 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 334
TABLE 392 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 334
TABLE 393 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 335
TABLE 394 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 335
TABLE 395 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 336
TABLE 396 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 336
TABLE 397 CHINA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 337
TABLE 398 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 338
TABLE 399 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 339
TABLE 400 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 339
TABLE 401 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 340
TABLE 402 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 340
TABLE 403 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 341
TABLE 404 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 341
TABLE 405 INDIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 342
TABLE 406 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 343
TABLE 407 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 343
TABLE 408 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 344
TABLE 409 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 344
TABLE 410 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 345
TABLE 411 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 345
TABLE 412 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 346
TABLE 413 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 346
TABLE 414 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 347
TABLE 415 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 348
TABLE 416 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 348
TABLE 417 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION) 349
TABLE 418 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 349
TABLE 419 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN,
2023-2030 (USD MILLION) 350
TABLE 420 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 350
TABLE 421 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER,
2023-2030 (USD MILLION) 351
TABLE 422 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 352
TABLE 423 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 352
TABLE 424 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 353
TABLE 425 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 353
TABLE 426 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 354
TABLE 427 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 354
TABLE 428 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 355
TABLE 429 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 355
TABLE 430 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 356
TABLE 431 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION) 357
TABLE 432 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 357
TABLE 433 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION) 358
TABLE 434 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 358
TABLE 435 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN,
2023-2030 (USD MILLION) 359
TABLE 436 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 359
TABLE 437 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER,
2023-2030 (USD MILLION) 360
TABLE 438 LATIN AMERICA: KEY MACROINDICATORS 361
TABLE 439 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 361
TABLE 440 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 361
TABLE 441 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 362
TABLE 442 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 362
TABLE 443 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION) 363
TABLE 444 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 363
TABLE 445 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,
2023-2030 (USD MILLION) 364
TABLE 446 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 364
TABLE 447 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER,
2023-2030 (USD MILLION) 365
TABLE 448 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 366
TABLE 449 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 366
TABLE 450 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 367
TABLE 451 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 367
TABLE 452 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 368
TABLE 453 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 368
TABLE 454 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 369
TABLE 455 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 369
TABLE 456 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 370
TABLE 457 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,
2023-2030 (USD MILLION) 371
TABLE 458 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 371
TABLE 459 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,
2023-2030 (USD MILLION) 372
TABLE 460 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 372
TABLE 461 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION) 373
TABLE 462 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 373
TABLE 463 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION) 374
TABLE 464 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 375
TABLE 465 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION) 375
TABLE 466 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 376
TABLE 467 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET,
BY PURCHASE MODE, 2023-2030 (USD MILLION) 376
TABLE 468 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 377
TABLE 469 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,
2023-2030 (USD MILLION) 377
TABLE 470 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 378
TABLE 471 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER,
2023-2030 (USD MILLION) 378
TABLE 472 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 380
TABLE 473 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION) 380
TABLE 474 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 381
TABLE 475 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET,
BY PURCHASE MODE, 2023-2030 (USD MILLION) 381
TABLE 476 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 382
TABLE 477 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN,
2023-2030 (USD MILLION) 382
TABLE 478 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 383
TABLE 479 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER,
2023-2030 (USD MILLION) 383
TABLE 480 OVERVIEW OF KEY STRATEGIES DEPLOYED BY MAJOR PLAYERS
IN IMMUNOASSAY MARKET 384
TABLE 481 IMMUNOASSAY MARKET: DEGREE OF COMPETITION 387
TABLE 482 IMMUNOASSAY MARKET: REGION FOOTPRINT 391
TABLE 483 IMMUNOASSAY MARKET: PRODUCT FOOTPRINT 392
TABLE 484 IMMUNOASSAY MARKET: SPECIMEN FOOTPRINT 393
TABLE 485 IMMUNOASSAY MARKET: LIST OF KEY STARTUPS/SME PLAYERS 396
TABLE 486 IMMUNOASSAY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/
SME PLAYERS, BY REGION 397
TABLE 487 IMMUNOASSAY MARKET: PRODUCT LAUNCHES/APPROVALS/ENHANCEMENTS, JANUARY 2022-JULY 2025 399
TABLE 488 IMMUNOASSAY MARKET: DEALS, JANUARY 2022-JULY 2025 400
TABLE 489 ABBOTT: COMPANY OVERVIEW 402
TABLE 490 ABBOTT: PRODUCTS OFFERED 403
TABLE 491 ABBOTT: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025 405
TABLE 492 ABBOTT: DEALS, JANUARY 2022-JUNE 2025 406
TABLE 493 ABBOTT: EXPANSIONS, JANUARY 2022-JUNE 2025 407
TABLE 494 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 408
TABLE 495 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 409
TABLE 496 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022-JUNE 2025 412
TABLE 497 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-JUNE 2025 412
TABLE 498 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022-JUNE 2025 413
TABLE 499 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 415
TABLE 500 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 416
TABLE 501 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022-JUNE 2025 418
TABLE 502 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022-JUNE 2025 418
TABLE 503 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022-JUNE 2025 419
TABLE 504 DANAHER: COMPANY OVERVIEW 421
TABLE 505 DANAHER: PRODUCTS OFFERED 422
TABLE 506 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025 423
TABLE 507 DANAHER: DEALS, JANUARY 2022-JUNE 2025 424
TABLE 508 DANAHER: EXPANSIONS, JANUARY 2022-JUNE 2025 425
TABLE 509 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 427
TABLE 510 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 428
TABLE 511 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS,
JANUARY 2022-JUNE 2025 429
TABLE 512 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-JUNE 2025 430
TABLE 513 REVVITY: COMPANY OVERVIEW 432
TABLE 514 REVVITY: PRODUCTS OFFERED 433
TABLE 515 REVVITY: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025 434
TABLE 516 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025 435
TABLE 517 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 436
TABLE 518 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 437
TABLE 519 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS,
JANUARY 2022-JUNE 2025 438
TABLE 520 DIASORIN S.P.A.: COMPANY OVERVIEW 439
TABLE 521 DIASORIN S.P.A.: PRODUCTS OFFERED 440
TABLE 522 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022-JUNE 2025 442
TABLE 523 DIASORIN S.P.A.: DEALS, JANUARY 2022-JUNE 2025 443
TABLE 524 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 444
TABLE 525 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 445
TABLE 526 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025 447
TABLE 527 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-JUNE 2025 448
TABLE 528 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 449
TABLE 529 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 450
TABLE 530 QUIDELORTHO CORPORATION: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025 453
TABLE 531 QUIDELORTHO CORPORATION: DEALS, JANUARY 2022-JUNE 2025 453
TABLE 532 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022-JUNE 2025 454
TABLE 533 BIOMERIEUX: COMPANY OVERVIEW 455
TABLE 534 BIOMERIEUX: PRODUCTS OFFERED 456
TABLE 535 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025 457
TABLE 536 BIOMERIEUX: DEALS, JANUARY 2022-JUNE 2025 458
TABLE 537 QIAGEN: COMPANY OVERVIEW 459
TABLE 538 QIAGEN: PRODUCTS OFFERED 460
TABLE 539 QIAGEN: DEALS, JANUARY 2022-JUNE 2025 461
TABLE 540 SYSMEX CORPORATION: COMPANY OVERVIEW 462
TABLE 541 SYSMEX CORPORATION: PRODUCTS OFFERED 464
TABLE 542 SYSMEX CORPORATION: DEALS, JANUARY 2022-JUNE 2025 464
TABLE 543 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022-JUNE 2025 465
TABLE 544 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 467
TABLE 545 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 468
TABLE 546 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022-JUNE 2025 469
TABLE 547 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-JUNE 2025 469
TABLE 548 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,
JANUARY 2022-JUNE 2025 470
TABLE 549 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 471
TABLE 550 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 472
TABLE 551 MERCK KGAA: COMPANY OVERVIEW 473
TABLE 552 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW 474
TABLE 553 BIO-TECHNE: COMPANY OVERVIEW 475
TABLE 554 CELLABS: COMPANY OVERVIEW 476
TABLE 555 ABNOVA CORPORATION: COMPANY OVERVIEW 477
TABLE 556 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW 477
TABLE 557 TOSOH CORPORATION (TOSOH BIOSCIENCES): COMPANY OVERVIEW 478
TABLE 558 CELL SCIENCES: COMPANY OVERVIEW 478
TABLE 559 ENZO BIOCHEM INC.: COMPANY OVERVIEW 479
TABLE 560 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 480
TABLE 561 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW 480
TABLE 562 ELABSCIENCE BIONOVATON INC.: COMPANY OVERVIEW 481
TABLE 563 WAK-CHEMIE MEDICAL GMBH: COMPANY OVERVIEW 481
TABLE 564 SERA CARE: COMPANY OVERVIEW 482
TABLE 565 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW 482
TABLE 566 KAMIYA BIOMEDICAL COMPANY: COMPANY OVERVIEW 483
TABLE 567 GYROS PROTEIN TECHNOLOGIES AB: COMPANY OVERVIEW 483
TABLE 568 TRIVITRON HEALTHCARE: COMPANY OVERVIEW 484
TABLE 569 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW 484
TABLE 570 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 485